Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Technologies, University of Michigan Partner on Research to Attack Prostate Cancer Using Systems Biology

Published: Monday, March 23, 2009
Last Updated: Monday, March 23, 2009
Bookmark and Share
Agilent Technologies announced its support of prostate cancer research by the University of Michigan’s Centre for Translational Pathology (MCTP) through a grant of instruments and funding.

The goal is to accelerate research to defeat the disease using a multidisciplinary systems biology approach.

 “We see this as an opportunity to partner with a truly advanced lab that is using multiple scientific disciplines to look at very important clinical problems,” said Gustavo Salem, Agilent Vice President and General Manager, Biological Systems Division. “This relationship will give us a better understanding of how to apply our technologies in a clinical research setting and will enable the University of Michigan to accelerate its scientific research.”

Agilent is contributing a 1200 Series liquid chromatography (LC) system to be used to separate metabolites from human plasma and a 1200 Series Rapid Resolution LC coupled to a 6530 Accurate Mass quadrupole time-of-flight mass spectrometer (Q-TOF MS) for the identification of those metabolites.

 “We will focus our laboratory research on a systems-biological approach to try to understand the disease at the biochemical and genetic levels simultaneously,” explained Christopher Beecher, Ph.D., Professor of Pathology at the U-M Medical School. “We expect to be able to make a number of discoveries in prostate cancer and to develop new techniques that will be useful universally.”

The research team, led by the director of the MCTP, Arul Chinnaiyan, M.D., Ph.D., has already revealed metabolomic profiles of prostate cancer progression by looking at 1,126 metabolites across 262 samples of tissue, blood or urine. The lab is currently trying to unlock the secrets of how prostate tumours gain the ability to spread. The MCTP houses cutting-edge facilities for genomic, proteomic and metabolomic analyses, the three main disciplines used in systems biology.

The collaboration between MCTP and Agilent is a result of Agilent’s University Relations Programme, which facilitates collaborations with universities around the world. The programme sponsors research that advances the science of measurement and provides instructional materials to universities.


Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Extends Agreement with PerkinElmer on Bioanalyzer Chips
PerkinElmer supplies chips for Agilent's popular 2100 Bioanalyzer system.
Thursday, January 21, 2016
Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent, Cell Line Genetics Collaborate
Companies to collaborate on high-throughput cell-line characterization services for regenerative medicine, cancer researchers.
Thursday, February 13, 2014
Agilent Joins Forces with Baylor College of Medicine
Collaboration will see Agilent and Baylor provide customized CGH microarrays for cancer, prenatal and postnatal research.
Thursday, November 14, 2013
Agilent and Seoul National University Hospital Collaborate
The strategic collaboration will focus on the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers.
Friday, October 18, 2013
Agilent Technologies to Separate into Two Public Companies
Life sciences, diagnostics and applied markets (LDA) that will retain the Agilent name, and the other company will be comprised of Agilent's electronic measurement (EM) products.
Monday, September 23, 2013
Agilent Technologies and SomaLogic Enter Agreement
The agreement will expand access to SomaLogic's unbiased protein biomarker discovery platform.
Tuesday, August 13, 2013
Agilent Technologies Announces Winner of Fifth Annual Early Career Professor Award
Assistant Professor at Northwestern Recognized for Cancer Diagnostics Research.
Friday, May 10, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Agilent and Applied Proteomics Will Collaborate
Collaboration to maximize capabilities of highly multiplexed protein assays.
Friday, March 08, 2013
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Technologies and Chungnam National University Collaborate to Further Glycomics Research
The university aims to identify and develop biomarkers for diseases.
Friday, August 26, 2011
Agilent Technologies Enters Second Phase of Collaboration to Map Human Proteome
Agilent’s collaboration with ISB and ETH Zurich for the mapping of the complete human proteome by mass spectrometry is enters its second phase.
Thursday, September 23, 2010
Agilent Updates Human Exon Target Enrichment Tool, Featuring Expressed Genome Content and Optimized Uniformity
The Latest SureSelect product to emerge from close collaboration with The Broad Institute.
Wednesday, August 25, 2010
Agilent and Los Alamos Develop First High-Throughput System to be Deployed at UCLA’s Global Bio Lab
Researchers are developing new tools for characterizing biological pathogens that could give rise to potentially deadly pandemics.
Thursday, June 11, 2009
Scientific News
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
How to Unlock Inaccessible Genes
An international team of biologists has discovered how specialized enzymes remodel the extremely condensed genetic material in the nucleus of cells in order to control which genes can be used.
Viral Gene Editing System Corrects Genetic Liver Disease
Penn study has implications for developing safe therapies for an array of rare diseases via new gene cut-and-paste methods.
Mapping Regulatory Elements
Systematically searching DNA for regulatory elements indicates limits of previous thinking
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
'Junk' DNA Plays Role in Preventing Breast Cancer
Supposed "junk" DNA, found in between genes, plays a role in suppressing cancer, according to new research by Universities of Bath and Cambridge.
Genome-Wide Study Yields Markers of Lithium Response
An international consortium of scientists has identified a stretch of chromosome that is associated with responsiveness to the mood-stabilizing medication lithium among patients with bipolar disorder.
A Cancer’s Surprise Origins, Caught in Action
First demonstration of a melanoma arising from a single cell.
Understanding the Mechanisms Blocking Cancer Cell Growth
DNA damage can lead to gene inactivation or deregulation and cause various diseases such as cancer; however, many DNA repair mechanisms allow cells to survive against such damage.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!